We are experiencing global outbreak of coronavirus (COVID-19) recently. Millions of people are suffering and dying every day, in spite of putting our best efforts. We are doing this survey to understand people’s reaction to this situation. The survey will ask about your knowledge, practices and worries. Your response will help us to understand how to better control these situations. Your feedback is highly important to us, as we need to find out the best way to stop the disease from spreading and killing thousands of lives, and to reduce the stress among the population.

The purpose of this project is to screen potential participants for multiple research studies being conducted by tobacco researchers at Penn State Hershey. Since there are multiple IRB approved studies enrolling at Penn State Hershey with similar but not identical inclusion/exclusion criteria, it is more efficient for the researchers and participants to have one phone number to call initially for basic screening. After completing this, the participant can be redirected for more specific screening if they are found to be potentially eligible for one of the studies.

Participants will fill out a 5-minute survey on tobacco use in order to find out which study they may be eligible for.

Depends on study

This study will investigate the changes in the human fecal microbiomes and resistomes in response to antibiotic treatment.

The scope of the study is to use a novel biologic drug, CC-93538, against symptoms of esophageal dysfunction and inflammation in subjects with Eosinophilic esophagitis (EoE). The CC-93538 will target the IL-13 receptor, a key driver of disease pathology in EoE. The phase 3 program will evaluate the safety and efficacy of CC-93538 in placebo-controlled Induction, Maintenance, and Open-Label Extension study.

The participants are required to sign the consent form. If you decide to participate, you will be required to attend study visits, follow doctor's instructions and take the study drug as instructed. You will be required to complete electronic questionnsires, and tell you doctor about any health problems, symptoms and drugs that you are taking. There are two visits during screening, including EGD procedure with biopsies. All the procedures during screening are done to determine if you are qualified to participate in the study. If the screening tests show that you can take part in this study, a computer program will make the assignment of which study drug you are to receive. You will be assigned to start the study by receiving either active drug (360 mg of CC-93538), or placebo. Both active drug and placebo will be given weekly by subcutaneous injection. You will be asked to have blood test done for serum and for biomarkers at most of your visits (except week 20). Physical exam and pregnancy's tests will be done at screening visit, and every visit during the induction after week 4. the ECG test will be done at screening. Similarly, the blood work and pregnancy's tests will be done at every visit during the maintenance. urinalysis and physical exam will also be done at some visits in the maintenance. Your vital signs will be monitored throughout the study.

$750 induction, $565 Maintenance max

Placebo-controlled efficacy and safety study of GSK3511294 in participants with severe asthma with an eosinophilic phenotype

There will be 19 in person visits over the course of 15 months where blood, EKGs, and other assessments will occur. You will receive the study drug every 26 weeks.

A study designed to evaluate the efficacy and safety of BGB-A1217 + tislelizumab compared with that of pembrolizumab in patients with PD-L1-selected NSCLC who have locally advanced or recurrent disease that is unresectable or not amenable to radiotherapy, with or without chemoradiotherapy, or previously untreated metastatic disease, and whose tumors do not harbor EGFR-sensitizing mutations or ALK translocations. The efficacy and safety of tislelizumab alone will be explored in a small cohort of the same patient population.

You will have the following exams, tests, or procedures done: Measurement of your height, weight, and vital signs (blood pressure, respiratory rate, pulse, and temperature) Complete physical exam Blood sample collection for the following tests: Safety laboratory tests. This may include routine tests and special blood chemistries, blood clotting, and blood counts to evaluate your overall health and thyroid, liver, pancreas, and kidney, and heart functions. Additional blood samples may be collected to perform routine blood tests, if your study doctor thinks it is necessary. Enzymes tests to check your muscle and heart function (Creatine kinase [CK] and creatine kinase muscle/brain [CK MB] isoenzyme or Troponin I or Troponin T) You will be tested for HIV, Hepatitis B virus and hepatitis C virus to check whether you are infected with these viruses. If a test shows that you have an active hepatitis B or C infection or HIV, you will have follow-up counselling and medical advice provided by the study doctor or study staff. If your test results are positive, you will be notified and the study doctor will be required by law to notify government health authorities. Signing this consent form means that you agree to have this testing. Urine sample collection for routine safety tests. If you are a woman and are able to become pregnant, you will have a urine or serum pregnancy test (must be negative to enter the study). An electrocardiogram (ECG) to look at the electrical activity of your heart. Pulmonary function test to check how your lungs are working and completion of questionnaires about your general health, well-being, and overall quality of life. Imaging to assess your tumor before starting treatment. A computerized series of x-rays (CT scan or Computed Tomography) will be performed. A series of pictures of the inside of your body created by magnetic energy (MRI scan or magnetic resonance imaging) may be done if a CT scan is not available or if this is considered a more appropriate test for your cancer by the study doctor. In addition, an MRI or CT of the head will be done to determine if there is any spread of the cancer to your brain. A type of imaging that uses a radioactive substance called tracer to look at your body (whole-body positron emission tomography (PET)/CT scan) or a bone scan may also be performed if your study doctor decides to do so. Rarely, color photography may be used to document skin metastases if you have any.

This study involves the use of a new medicine known as ISIS 721744 as a new treatment for Hereditary Angioedema, which is designed to lower the amount of a protein, known as prekallikrein (PKK), which is made by your liver. When PKK is made by the liver and released into your blood stream, it can lead to Hereditary Angioedema attacks. Therefore, the purpose of this study is to assess if reducing the amount of PKK can reduce your HAE attacks and to see how safe ISIS 721744 is for patients with HAE.

There will be 11 in-person visits over 11 months that you will need to come to where there will be blood drawn, as well as other assesments. You will receive and injection of the study drug once a month.

This research study will test an investigational medication called KVD900, a new oral drug being developed to treat hereditary angioedema, the same condition you have. This study is being done to understand how well one or two doses of KVD900 300mg or KVD900 600mg works against placebo to bring relief from an attack of HAE.

If you decide to take part in the study, you will come to the site for 2 visits, and you will have 4 televisits, which may be done by phone or video. Your participation in the study will be approximately 25 weeks. You will need to complete a study e-diary that will use an app that will be downloaded onto your personal mobile device, or on a mobile device provided to you for the purpose of this study. We will perform vital signs, a physical exam, an electrocardiogram (ECG), pregnancy test, and blood collection. In this study every patient will treat one attack with 300mg of study drug, one attack with 600mg of study drug, and one attack with placebo. If after 3 hours following your first dose of study drug you do not experience the needed relief, your assigned kit includes a second dose of study drug that you may take for the attack. The second dose is the same treatment as the first dose. If after 1 hour of your second dose of study drug you do not experience the needed relief, you may dose with your conventional medication.

Up to $1,050

This is a pilot study on the impact of switching from cigarettes to Electronic Cigarettes on disease-related clinical symptoms and biomarkers of harm in smokers with preexisting COPD

You will be asked to reduce your cigarette smoking and use study-provided e-cigarettes for one year. You will be asked to attend 5 in-person visits at the Hershey Medical Center and participate in 10 telephone visits. Throughout the study you will be asked to complete questionnaires, have heart rate, blood pressure and pulse oximetry taken, electrocardiograms (ECGs), height and weight measured, provide medical history, perform pulmonary function tests, complete a 6-minute walk, have your exhaled carbon monoxide measured, provide urine specimen and have blood drawn.

PHVS416 (PHA-022121 soft capsules) is being developed for the treatment of HAE. The main purpose of this research study is to test the effectiveness of different doses of study drug in preventing HAE attacks. Within this study, PHVS416 will be compared to a placebo.

This study is being done to study the efficacy of KVD824 as prophylaxis treatment for attacks of HAE (meaning whether or not it works to prevent the occurrence of attacks) in your body. KalVista has designed this study to understand the effect of KVD824 at 3 different dose levels and investigate more about how safe KVD824 is (to find out what effects - good and bad - KVD824 has) when compared with a placebo. Placebo looks like KVD824 but contains no active drug.

The study has a “Screening Period” that starts with a Screening Visit and follows with a “Run-In”-; a Randomization Visit; and a “Treatment period” ending with the End of Treatment Visit. You will have approximately 6 study appointments or “visits” where different procedures will take place such as blood draws, ekg's, and physical exams.

This study looks at understanding eating behaviors and attitudes toward food in children/adolescents. More specifically the study's goal is to compare those with and without food allergies to gain a better understanding of a possible underlying factor towards certain behaviors. Children and their caregivers will complete a survey composed of a short section on the child's medical history regarding allergies followed with questions in commonly used clinical assessments.

Site For VIOLET

Non-inferiority study of GSK3511294 compared with mepolizumab or benralizumab in participants with severe asthma with an eosinophilic phenotype.

You will receive either study drug or placebo, undergo research-related tests and procedures, and questionnaires. You will need to visit the study center up to 18 times over a period of 15 months. You will have different tests and procedures throughout the study. The aim is to check on your health and symptoms, check on your response to treatment and any side effects, and assess the study drug. This study will compare the study drug with either mepolizumab or benralizumab, known as the comparator medications. The effects of the drugs, both good and bad, will be compared. Study participants will be divided into 2 groups to receive: Study drug (once every 26 weeks) + placebo (once every 4 or 8 weeks) OR, Mepolizumab (once every 4 weeks) or benralizumab (once every 8 weeks) + placebo (once every 26 weeks). All participants will receive an active treatment. You will be assigned to receive either the study drug or comparator (mepolizumab or benralizumab) you were taking before the study. No participant previously taking mepolizumab will be assigned to benralizumab, and no participant previously taking benralizumab will be assigned to mepolizumab.

$183.00

Wheezing is a common symptom of respiratory distress in infants and children. Infants who wheeze are at increased risk of being diagnosed with asthma, the most common chronic disease of childhood. This study will aims to yield an objective measure of asthma risk using molecular markers obtained from saliva. Saliva miRNA (markers used in this study) levels will be measured using HiSeq technology. Refinement and validation of this measure in future large-scale studies could allow clinicians to accurately predict for families an infant’s risk of asthma and optimize medical management to prevent future hospitalizations.

If your child has a respiratory illness you will be asked to provide a saliva sample at one clinic visit. Six months after the initial encounter, you will be asked to do complete surveys designed to be done remotely at home.

$20.00

A study to evaluate the effectiveness and safety of the study drug Pamrevlumab (FG-3019) in participants with Idiopathic Pulmonary Fibrosis (IPF)

During this study, you will be asked to come to in-person visits at the Hershey Medical Center every 3 weeks for a total of 48 weeks. Throughout the study, you will be asked to complete questionnaires, have heart rate, blood pressure and pulse oximetry taken, electrocardiograms (ECGs), height and weight measured, provide medical history, receive study drug infusions, have physical exams, perform pulmonary function tests, have blood drawn and get CT (computed tomography) scans.

A phase 3 clinical trial to investigate the effectiveness and safety of a study drug in subjects in Idiopathic Pulmonary Fibrosis

You will be required to attend 8 in-person visits at the Hershey Medical Center over the span of approximately one year. During the study you will have physical examinations, complete questionnaires, review your medical history and current medications, have vital signs and ECGs taken, have blood tests performed, complete pulmonary function testing, and potentially have a high resolution CT scan done. You will take the inhaled treprostinil or placebo daily at home throughout the study.

BMN 331 is an experimental drug that is being tested for the treatment of patients with HAE. This study is the first time BMN 331, which is a gene therapy, is being used in humans. BMN 331 is given only once during this research study and it is given as an infusion. The purpose of this study is to find out what effects, good and/or bad, the Study Drug has on you and your HAE.

You will have a total of 68 in person visits over 68 months where there will be blood drawn and other lab tests. You will have to travel to an off site location to receive the drug once and travel will be paid for by the sponsor of the trial.